September 2023 in “Nature communications” Alk1 in specific cells is crucial for proper nerve branching and hair function.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
4 citations
,
March 2024 in “Developmental Dynamics” ALX4 is crucial for normal craniofacial and hair development, with specific roles in different cell types.
66 citations
,
April 1989 in “Alcoholism Clinical and Experimental Research” The ethanol patch test reliably identifies ALDH phenotype.
February 2026 in “Australasian Journal of Dermatology” A new tool simplifies alopecia areata severity scoring but needs validation.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
1 citations
,
July 2024 in “PharmacoEconomics - Open” The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
4 citations
,
November 2018 in “Journal of pharmacological sciences” Mild exercise reduces pain in older rats through a brain chemical, while intense exercise reduces pain in all rats through a different pain-blocking process.
24 citations
,
June 2021 in “Journal of the European Academy of Dermatology and Venereology” Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
August 2023 in “Sabuncuoglu Serefeddin Health Sciences” CT60 polymorphism might increase the risk of Alopecia Areata.
34 citations
,
August 2015 in “Frontiers in Behavioral Neuroscience” Allopregnanolone affects fear responses differently in male and female rats, possibly explaining sex differences in anxiety disorders.
2 citations
,
August 2021 in “Photodiagnosis and Photodynamic Therapy” Using 5-aminolevulinic acid photodynamic therapy for hair loss didn't increase hair growth but slightly reduced scalp oiliness, and it was safe with mild side effects.
April 2016 in “Journal of The American Academy of Dermatology” AGA patients have a lower quality of life than AA patients.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
1 citations
,
January 2023 in “eCite Digital Repository (University of Tasmania)” Al tolerance in wheat involves complex mechanisms beyond just malate efflux, including root growth and nutrient differences.
January 2025 in “Indian Journal of Unani Medicine” Wet cupping may improve hair health in androgenetic alopecia without side effects.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Disease-specific tools better assess quality of life in alopecia areata patients.
11 citations
,
November 2006 in “Journal of Veterinary Diagnostic Investigation” An alpaca acted like a male and couldn't have babies because of a benign tumor in its ovary that caused high testosterone levels.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
5 citations
,
April 2024 in “JAAD International” AI can accurately measure hair loss severity in alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.
November 2025 in “Figshare” SQSTM1 is linked to increased risk of alopecia areata.